CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico

Pharmacogenomics

Volumn 15, Issue 3, 2014, Pages 339-348

  Lazalde Ramos, Blanca Patricia ^a   Martínez Fierro, Margarita De La Luz ^a   Galaviz Hernández, Carlos ^b   Garza Veloz, Idalia ^a   Naranjo, María Eugenia G ^c   Sosa Macías, Martha ^b   Llerena, Adrián ^c  

^a UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

^b Desarrollo Integral Regional Unidad Durango IPN   (Mexico)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

allele frequency; CYP2D6polymorphism; Mexican indigenous; pharmacogenetics; predicted phenotype

Indexed keywords

ALLELES; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENOTYPE; HUMANS; INDIANS, NORTH AMERICAN; METABOLIC DETOXICATION, DRUG; MEXICO; PHENOTYPE;

EID: 84894430339     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.203     Document Type: Article

References (55)

1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2005).
2. LLerena A, Dorado P, Penas-Lledo EM. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10(1), 17-28 (2009).
3. Teh LK, Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab. Pharmacokinet. 27(1), 55-67 (2012).
4. LLerena A, Dorado P, Penas-Lledo EM, Caceres MC, De La Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J. 7(6), 408-410 (2007).
5. Ladero JM, Benitez J, Jara C et al. Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology 48(2), 107-110 (1991).
6. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 48(11), 689-723 (2009).
7. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 23-37 (2004).
8. Casner PR. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J. Clin. Pharmacol. 45(11), 1230-1235 (2005).
9. Sosa-Macias M, Dorado P, Alanis-Banuelos RE, LLerena A, Lares-Asseff I. Influence of CYP2D6 deletion, multiplication,-1584C->G, 31G->A and 2988G->a gene polymorphisms on dextromethorphan metabolism among Mexican Tepehuanos and Mestizos. Pharmacology 86(1), 30-36 (2010).
10. Dorado P, Heras N, Machin E, Hernandez F, Teran E, LLerena A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur. J. Clin. Pharmacol. 68(5), 637-644 (2012).
11. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997).
12. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274(1), 516-520 (1995).
13. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278(1), 441-446 (1996).
14. Sosa-Macias M, Elizondo G, Flores-Perez C et al. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J. Clin. Pharmacol. 46(5), 527-536 (2006).
15. Salazar-Flores J, Torres-Reyes LA, Martinez-Cortes G et al. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. Genet. Test. Mol. Biomarkers 16(9), 1098-1104 (2012).
16. Contreras AV, Monge-Cazares T, Alfaro-Ruiz L et al. Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos. Pharmacogenomics 12(5), 745-756 (2011).
17. Lopez M, Guerrero J, Jung-Cook H, Alonso ME. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur. J. Clin. Pharmacol. 61(10), 749-754 (2005).
18. Sandoval K, Buentello-Malo L, Penaloza-Espinosa R et al. Linguistic and maternal genetic diversity are not correlated in native Mexicans. Hum. Genet. 126(4), 521-531 (2009).
19. Rangel-Villalobos H, Martinez-Sevilla VM, Salazar-Flores J et al. Forensic parameters for 15 STRs in eight Amerindian populations from the north and west of Mexico. Forensic Sci. Int. Genet. 7(3), e62-e65 (2013).
20. Rodeiro I, Remirez-Figueredo D, Garcia-Mesa M, Dorado P, LLerena A. Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders. Drug Metabol. Drug Interact. 27(1), 57-60 (2012).
21. Dorado P, Caceres M, Pozo-Guisado E, Wong ML, Licinio J, LLerena A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39(Suppl. 10), S571-S574 (2005).
22. LLerena A, Dorado P, Ramirez R et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. 12(2), 176-183 (2012).
23. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
24. Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab. Pharmacokinet. 27(1), 9-54 (2012).
25. Munoz S, Vollrath V, Vallejos MP et al. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 8(4), 343-351 (1998).
26. Jurima-Romet M, Foster BC, Casley WL et al. CYP2D6-related oxidation polymorphism in a Canadian Inuit population. Canadian J. Physiol. Pharmacol. 75(3), 165-172 (1997).
27. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 9(2), 217-228 (1999).
28. Roco A, Quinones L, Agundez JA et al. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations. Front. Genet. 3, 229 (2012).
29. Nowak MP, Tyndale RF, Sellers EM. CYP2D6 phenotype and genotype in a Canadian Native Indian population. Pharmacogenetics 7(2), 145-148 (1997).
30. Griman P, Moran Y, Valero G, Loreto M, Borjas L, Chiurillo MA. CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: pharmacogenetics and anthropological implications. Ann. Hum. Biol. 39(2), 137-142 (2012).
31. Bailliet G, Santos MR, Alfaro EL et al. Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay. Mutat. Res. 627(2), 171-177 (2007).
32. Agundez JA, Ramirez R, Hernandez M, LLerena A, Benitez J. Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. Pharmacogenetics 7(4), 337-340 (1997).
33. Isaza CA, Henao J, Lopez AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find. Exp. Clin. Pharmacol. 22(9), 695-705 (2000).
34. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19(2), 170-179 (2009).
35. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the-1584G promoter polymorphism. Clin. Chem. 49(6 Pt 1), 1008-1011 (2003).
36. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther. 65(5), 570-575 (1999).
37. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46(3), 452-459 (1994).
38. Chou WH, Yan FX, De Leon J et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 20(2), 246-251 (2000).
39. Bijl MJ, Visser LE, van Schaik RH et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin. Pharmacol. Ther. 85(1), 45-50 (2009).
40. Fux R, Morike K, Prohmer AM et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin. Pharmacol. Ther. 78(4), 378-387 (2005).
41. Rau T, Wuttke H, Michels LM et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol. Ther. 85(3), 269-272 (2009).
42. Berecz R, LLerena A, de la Rubia A et al. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35(6), 231-234 (2002).
43. LLerena A, Berecz R, de la Rubia A, Fernandez-Salguero P, Dorado P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 23(6), 616-620 (2001).
44. Berecz R, Dorado P, de la Rubia A, Caceres MC, Degrell I, LLerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Curr. Drug Targets 5(6), 573-579 (2004).
45. Mclellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7(3), 187-191 (1997).
46. Fonne-Pfister R, Meyer UA. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem. Pharmacol. 37(20), 3829-3835 (1988).
47. Dalen P, Frengell C, Dahl ML, Sjoqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther. Drug Monit. 19(5), 543-544 (1997).
48. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 28(1), 78-83 (2008).
49. Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J. Clin. Pharm. Ther. 31(5), 493-502 (2006).
50. Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultrarapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7(4), 257-265 (2007).
51. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J. Clin. Psychopharmacol. 24(6), 647-652 (2004).
52. Gonzalez I, Penas-Lledo EM, Perez B, Dorado P, Alvarez M, LLerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9(7), 833-840 (2008).
53. Ortet G, Ibanez MI, LLerena A, Torrubia R. The underlying traits of the Karolinska scales of personality (KSP). Eur. J. Psychol. Assess. 18(2), 139-148 (2002).
54. Penas-Lledo EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-Garcia E, LLerena A. CYP2D6 and the severity of suicide attempts. Pharmacogenomics 13(2), 179-184 (2012).
55. Penas-Lledo EM, Dorado P, Aguera Z et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol. Psychiatry 16(7), 691-692 (2011).